The Rise of Virtual Care in Hematology and Oncology: A Comprehensive Review

By Staff Writer

September 11, 2023

The demand for continuous home and institutional care is escalating due to the ageing population and the increasing prevalence of chronic diseases. This demand is further amplified by the current context of limited professional resources. The COVID-19 pandemic has fast-tracked the deployment of virtual care tools, ensuring access to care and services while promoting continuity of care.

Virtual care modalities have been integrated into care pathways and are increasingly used in the evaluation, treatment, and follow-up of patients in specialty medicine, including haematology and oncology. These modalities have the potential to improve access to health care for most patients and foster their engagement in managing their illness.

A scoping review of scientific and grey literature conducted over the past five years by  the Institut national d’excellence en santé et en services sociaux (INESSS) has shed light on the care pathways that can be supported or optimised with the use of virtual care. Teleconsultation and tele-education have emerged as the most studied interventions in the care pathways of haematology and oncology.

The Potential and Concerns of Virtual Care in Oncology and Hematology

Despite the promising results, the number of studies exploring the efficacy of virtual care interventions in individuals with malignant or non-malignant homoeopathy remains limited. Similarly, few studies have investigated the impact of virtual care interventions according to the type of cancer, the disease stage, or the treatment protocol.

Virtual care modalities reported as having a positive impact include telemedicine, telehealth, e-health/mobile health, teleconsultation, tele intervention, and tele-education. Individuals with cancer or a hematologic disease, or cancer survivors, use these tools alone or in combination with other modalities to improve their quality of life and reduce their disease- and treatment-related symptoms.

Despite the potential benefits, some patients and health professionals have expressed concerns about the use of virtual care. These include worries about the ability to use new technology, problems with the technology, feeling distant and insecure, the lack of face-to-face contact and communication with health professionals, and the failure to recognize their signs of distress.

While the use of virtual care in haematology and oncology shows promise, more high-quality studies are necessary to fully understand its potential and address any concerns. As we continue to navigate the challenges posed by the COVID-19 pandemic, the role of virtual care in specialty medicine is likely to become increasingly important.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.